Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran in Scleroderma-ILD
NCT02426229Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Feb 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dabigatran etexilate oral solution in scleroderma and interstitial lung disease (ILD), sponsored by Medical University of South Carolina. Primary endpoint: Composite Safety of dabigatran patients with scleroderma interstitial lung disease at 6 months. Started Feb 2016; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
sclerodermainterstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT02426229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426229.